Top

Published in:

Open Access 01-12-2024 | Lung Cancer | Case Report

Lung adenocarcinoma discovered during the follow-up of lung-dominant connective tissue disease: a case report and literature review

Authors: Zi Heng Zhu, Yi Guo, Xiao Yin Wang, Xian Wen Sun

Published in: BMC Pulmonary Medicine | Issue 1/2024

Abstract

Interstitial lung disease (ILD) can lead to lung cancer, which brings great challenges to differential diagnosis and comprehensive treatment. However, the clinical features of lung-dominant connective tissue disease (LD-CTD) related ILD combined with lung cancer has not been validated. We report the case of an 80-year-old woman with LD-CTD treated regularly with nintedanib who presented progressive dyspnoea and hypoxemia after recurrent viral infections. Her chest computed tomography (CT) showed aggravated interstitial fibrosis in both lower lungs with moderate right pleural effusion. Clinicians should be alert to lung cancer in patients who are experiencing poor responsiveness to treatment or acute progression of ILD. The available literatures about the differential diagnosis of clinical manifestations, imaging, treatment and prognosis of LD-CTD are reviewed and discussed in this study.

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–47. https://doi.org/10.1164/rccm.202202-0399ST. PMID:35486072.CrossRefPubMedPubMedCentral

Pereira DA, Dias OM, Almeida GE, et al. Lung-dominant connective tissue disease among patients with interstitial lung disease: prevalence, functional stability, and common extrathoracic features. J Bras Pneumol. 2015;41(2):151–60. PMID: 25972968; PMCID: PMC4428852.

Joy GM, Arbiv OA, Wong CK, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev. 2023;32(167):220210. PMID: 36889782; PMCID: PMC10032591.CrossRefPubMedPubMedCentral

Kondoh Y, Makino S, Ogura T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021;59(6):709–40. https://doi.org/10.1016/j.resinv.2021.04.011. Epub 2021 Oct 1. PMID: 34602377.CrossRefPubMed

Karampitsakos T, Spagnolo P, Mogulkoc N et al. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe. Respirology. 2023;28(1):56–65. https://doi.org/10.1111/resp.14363. PMID: 36117239.

Mohamed S, Bayoumi H, El-Aziz NA, et al. Prevalence, risk factors, and impact of lung Cancer on outcomes of idiopathic pulmonary fibrosis: a study from the Middle East. Multidiscip Respir Med. 2018;13:37. https://doi.org/10.1186/s40248-018-0150-7. PMID: 30305901; PMCID: PMC6169083.CrossRefPubMedPubMedCentral

Watanabe S, Saeki K, Waseda Y, et al. Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. J Thorac Dis. 2018;10(2):799–807. https://doi.org/10.21037/jtd.2017.12.134. PMID: 29607151; PMCID: PMC5864671.CrossRefPubMedPubMedCentral

Enomoto Y, Inui N, Yoshimura K, et al. Lung cancer development in patients with connective tissue disease-related interstitial lung disease: a retrospective observational study. Med (Baltim). 2016;95(50):e5716. https://doi.org/10.1097/MD.0000000000005716. PMID: 27977621; PMCID: PMC5268067.CrossRef

AK AK, Mantri SN, Lymphangitic Carcinomatosis. 2023 Jul 4. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32809756.

10.

Jreige M, Dunet V, Letovanec I, et al. Pulmonary lymphangitic carcinomatosis: diagnostic performance of high-resolution CT and 18F-FDG PET/CT in correlation with clinical pathologic outcome. J Nucl Med. 2020;61(1):26–32. https://doi.org/10.2967/jnumed.119.229575. Epub 2019 Jun 21. PMID: 31227574.CrossRefPubMed

11.

Klimek M. Pulmonary lymphangitis carcinomatosis: systematic review and meta-analysis of case reports, 1970–2018. Postgrad Med. 2019;131(5):309–318. https://doi.org/10.1080/00325481.2019.1595982. Epub 2019 Apr 5. PMID: 30900501.

12.

Ratwani AP, Ahmad KI, Barnett SD et al. Connective tissue disease-associated interstitial lung disease and outcomes after hospitalization: A cohort study. Respir Med. 2019;154:1–5. https://doi.org/10.1016/j.rmed.2019.05.020. Epub 2019 Jun 4. PMID: 31176795.

13.

Alhamad EH, Al-Kassimi FA, Alboukai AA et al. Comparison of three groups of patients with usual interstitial pneumonia. Respir Med. 2012;106(11):1575-85. https://doi.org/10.1016/j.rmed.2012.07.009. Epub 2012 Aug 5. PMID: 22871461.

14.

Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769–786. doi: 10.1016/S0140-6736(22)01052-2. Epub 2022 Aug 11. PMID: 35964592.

15.

Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2021;31(3):e2179. https://doi.org/10.1002/rmv.2179. Epub 2020 Oct 9. PMID: 33035373; PMCID: PMC7646051.CrossRefPubMed

16.

Liu Y, Zhou X,Liu X, et al. Systematic review and meta-analysis of the CT imaging characteristics of infectious pneumonia. Ann Palliat Med. 2021;10(10):10414–24. https://doi.org/10.21037/apm-21-2101.PMID:34763487.CrossRefPubMed

17.

Niitsu T, Fukushima K, Komukai S, et al. Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease. RMD Open. 2023;9(1):e002667. https://doi.org/10.1136/rmdopen-2022-002667. PMID: 36690385; PMCID: PMC9872509.CrossRefPubMedPubMedCentral

18.

Brehm TT, van der Meirschen M, Hennigs A, et al. Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. Sci Rep. 2021;11(1):5803. https://doi.org/10.1038/s41598-021-85081-0. PMID: 33707550; PMCID: PMC7970952.CrossRefPubMedPubMedCentral

19.

Amati F, Stainer A, Mantero M, et al. Lung microbiome in idiopathic pulmonary fibrosis and other interstitial lung diseases. Int J Mol Sci. 2022;23(2):977. https://doi.org/10.3390/ijms23020977. PMID:35055163.CrossRefPubMedPubMedCentral

20.

Li L, Wang C, Sun L, et al. Clinical characteristics and prognostic risk factors of mortality in patients with interstitial lung diseases and viral infection: a retrospective cohort study. J Med Microbiol. 2021;70(11):001449. https://doi.org/10.1099/jmm.0.001449. PMID: 34738890; PMCID: PMC8742552.CrossRefPubMedPubMedCentral

21.

Shao C, Shi Y, Chen R et al. Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic. J Med Virol. 2023;95(9):e29098. https://doi.org/10.1002/jmv.29098. PMID: 37707416.

22.

Garmendia I, Varthaman A, Marmier S et al. Acute Influenza Infection Promotes Lung Tumor Growth by Reprogramming the Tumor Microenvironment. Cancer Immunol Res. 2023;11(4):530–545. https://doi.org/10.1158/2326-6066.CIR-22-0534. PMID: 36883368.

23.

Weng CF, Chen LJ, Lin CW, et al. Association between the risk of lung cancer and influenza: a population-based nested case-control study. Int J Infect Dis. 2019;88:8–13. https://doi.org/10.1016/j.ijid.2019.07.030. Epub 2019 Jul 30. PMID: 31374345.CrossRefPubMed

24.

Nayebirad S, Mohamadi A, Yousefi-Koma H, et al. Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis. BMJ Open Respir Res. 2023;10(1):e002076. https://doi.org/10.1136/bmjresp-2023-002076. PMID: 38030264; PMCID: PMC10689422.CrossRefPubMedPubMedCentral

25.

Samarelli AV, Masciale V, Aramini B, et al. Molecular mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development. Int J Mol Sci. 2021;22(22):12179. https://doi.org/10.3390/ijms222212179. PMID: 34830058; PMCID: PMC8624248.CrossRefPubMedPubMedCentral

26.

Treppo E, Toffolutti F, Manfrè V, et al. Risk of Cancer in connective tissue diseases in northeastern Italy over 15 years. J Clin Med. 2022;11(15):4272. https://doi.org/10.3390/jcm11154272. PMID: 35893361; PMCID: PMC9332163.CrossRefPubMedPubMedCentral

27.

Beydon M, Pinto S, De Rycke Y, et al. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. Lancet Reg Health Eur. 2023;35:100768. https://doi.org/10.1016/j.lanepe.2023.100768. PMID: 37954220; PMCID: PMC10637983.CrossRefPubMedPubMedCentral

28.

Li N, Gao L, Bai C, et al. Clinical features and prognosis of lung cancer in patients with connective tissue diseases: a retrospective cohort study. Front Oncol. 2023;13:1167213. https://doi.org/10.3389/fonc.2023.1167213. PMID: 37342191; PMCID: PMC10277622.CrossRefPubMedPubMedCentral

29.

Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010;138(2):251–6. https://doi.org/10.1378/chest.10-0194. PMID: 20682528; PMCID: PMC3662187.CrossRefPubMedPubMedCentral

30.

Cottin V. Significance of connective tissue diseases features in pulmonary fibrosis. Eur Respir Rev. 2013;22(129):273– 80. https://doi.org/10.1183/09059180.00003013. PMID: 23997055; PMCID: PMC9487358.

31.

Nieto MA, Huang RY, Jackson RA et al. EMT: 2016. Cell. 2016; 166(1): 21–45. https://doi.org/10.1016/j.cell.2016.06.028. PMID:27368099.

32.

Sarrand J, Soyfoo MS. Involvement of epithelial-mesenchymal transition (EMT) in Autoimmune diseases. Int J Mol Sci. 2023;24(19):14481. https://doi.org/10.3390/ijms241914481. PMID: 37833928; PMCID: PMC10572663.CrossRefPubMedPubMedCentral

Title: Lung adenocarcinoma discovered during the follow-up of lung-dominant connective tissue disease: a case report and literature review
Authors: Zi Heng Zhu
Yi Guo
Xiao Yin Wang
Xian Wen Sun
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Pleural Effusion
Computed Tomography
Computed Tomography
Pityriasis Lichenoides Chronica
Nintedanib
Published in: BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-024-02975-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Chronic obstructive pulmonary disease burden, grades and erythrocytosis at a tertiary hospital in western Uganda

The impact of comorbidities on prolonged mechanical ventilation in patients with chronic obstructive pulmonary disease

Patient experience with bronchoscopy: topical versus monitored anesthesia

ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases

Clinical characteristics and mortality predictors among very old patients with pulmonary thromboembolism: a multicenter study report

Effectiveness and safety of awake prone positioning in COVID-19-related acute hypoxaemic respiratory failure: an overview of systematic reviews

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials